ArticleEULAR rheumatology open2026
Radiomics to discriminate between axial spondyloarthritis and axial psoriatic arthritis and to predict TNFi therapy persistence.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Axial spondyloarthritis (axSpA) and axial psoriatic arthritis (axPsA) represent entities with ongoing debate regarding their classification as distinct diseases or variants of the same condition. Although magnetic resonance imaging (MRI) is instrumental in diagnosing, traditional assessment may not fully capture subtle differences between them. This study aims to investigate whether radiomic features extracted from sacroiliac joint (SIJ) bone marrow oedema (BME) on MRI can discriminate between axSpA and axPsA, and predict tumour necrosis factor inhibitor (TNFi) therapy persistence in patients with axSpA. Methods: We included patients who underwent an SIJ MRI at our hospital. BME regions were segmented on short-tau inversion-recovery sequences, and 120 standardised radiomic features were extracted using PyRadiomics. For diagnostic discrimination, an XGBoost algorithm was employed and evaluated through 5-fold cross-validation. For patients with axSpA who initiated TNFi therapy, an exploratory Cox regression analysis was performed to identify radiomic predictors of treatment persistence. Results: We analysed MRI scans from 66 patients (41 axSpA, 25 axPsA). The XGBoost classifier achieved an accuracy of 0.80 ± 0.07 and area under the receiver operating characteristic curve of 0.77 ± 0.09 in differentiating axSpA from axPsA. The most discriminative features included texture parameters, shape characteristics, and grey-level intensity distributions. For TNFi persistence, multivariate Cox regression identified 2 shape-based features as independent predictors: increased sphericity, associated with discontinuation risk (hazard ratio [HR] 2.10, 95% CI: 1.09-4.05), while increased elongation showed a protective effect (HR 0.50, 95% CI: 0.25-0.99). Conclusions: This proof-of-concept study suggests radiomic SIJ BME features may help differentiate axSpA and axPsA and could be associated with TNFi persistence in patients with axSpA. These preliminary findings suggest that these conditions may exhibit distinct radiomic phenotypes.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.